Journal of Medicinal Chemistry & Toxicology

OMMEGA Publishers
Answering Intelligence
www.ommegaonline.org

Short communication Open Access

Active Targeted Nanoparticles for Anti–Cancer Nano Drugs Delivery across the Blood–Brain Barrier for Human Brain Cancer Treatment, Multiple Sclerosis (MS) and Alzheimer's Diseases Using Chemical Modifications of Anti–Cancer Nano Drugs or Drug–Nanoparticles through Zika Virus (ZIKV) Nanocarriers under Synchrotron Radiation

Alireza Heidari*

Faculty of Chemistry, California South University, 14731 Comet St. Irvine, CA 92604, USA

***Corresponding authors:** Alireza Heidari, Faculty of Chemistry, California South University (CSU), 14731 Comet St. Irvine, CA 92604, USA. E-mail: Scholar.Researcher.Scientist@gmail.com

Citation: Alireza Heidari. Active Targeted Nanoparticles for Anti–Cancer Nano Drugs Delivery across the Blood–Brain Barrier for Human Brain Cancer Treatment, Multiple Sclerosis (MS) and Alzheimer's Diseases Using Chemical Modifications of Anti–Cancer Nano Drugs or Drug–Nanoparticles through Zika Virus (ZIKV) Nanocarriers under Synchrotron Radiation. (2017) J Med Chem Toxicol 2(2): 90-94.

Received Date: July 3, 2017
Accepted Date: September 25, 2017
Published Date: October 3, 2017

DOI: 10.15436/2575-808X.17.1594

Short Communication

The demand for active targeted nanoparticles for anti–cancer Nano drugs delivery across the blood–brain barrier for human brain cancer treatment, Multiple Sclerosis (MS) and Alzheimer's diseases using chemical modifications of anti–cancer Nano drugs or drug–nanoparticles through Zika Virus (ZIKV) nanocarriers under synchrotron radiation has been significantly increasing in the world market due to their increased applications for various end uses[1-42]. The high crystalline nature of active targeted nanoparticles for anti–cancer Nano drugs delivery across the blood–brain barrier for human brain cancer treatment, Multiple Sclerosis (MS) and Alzheimer's diseases using chemical modifications of anti–cancer Nano drugs or drug–nanoparticles through Zika Virus (ZIKV) nanocarriers under synchrotron radiation and physically hydrophobic nature serves as barrier for easy processing. Active targeted nanoparticles for anti–cancer Nano drugs delivery across the blood–brain barrier for human brain cancer treatment, Multiple Sclerosis (MS) and Alzheimer's diseases using chemical modifications of anti–cancer Nano drugs or drug–nanoparticles through Zika Virus (ZIKV) nanocarriers under synchrotron radiation is usually treated with caustic to make them hydrophilic but they lead to decrease in strength but lipase treatment limited only to surface of active targeted nanoparticles for anti–cancer Nano drugs delivery across the blood–brain barrier for human brain cancer treatment, Multiple Sclerosis (MS) and Alzheimer's diseases using chemical modifications of anti–cancer Nano drugs or drug–nanoparticles through Zika Virus (ZIKV) nanocarriers under synchrotron radiation as the enzymes are bulky in nature they cannot penetrate into the polymeric chain of active targeted nanoparticles for anti–cancer Nano drugs delivery across the blood–brain barrier for human brain cancer treatment, Multiple Sclerosis (MS) and Alzheimer's diseases using chemical modifications of anti–cancer Nano drugs or drug–nanoparticles through Zika Virus (ZIKV) nanocarriers under synchrotron radiation and their strength is not reduced. An attempt has been made to make the fiber hydrophilic in nature. This short communication gives the process of treating active targeted nanoparticles for anti–cancer Nano drugs delivery across the blood–brain barrier for human brain cancer treatment, Multiple Sclerosis (MS) and Alzheimer's diseases us-

ing chemical modifications of anti–cancer Nano drugs or drug–nanoparticles through Zika Virus (ZIKV) nanocarriers under synchrotron radiation with ester cleaving enzyme lipase from bacterial species bacillus sp. As a result of lipase treatment, it is observed that their hydrophilic property is improved which is tested by capillary raise wicking test and drop dissipations test. The increase in the number of hydrophilic groups like –COOH and –OH due to the cleavage of polyethylene terephthalate ester may be the reason for improved hydrophilicity. The increase in presence of –COOH and –OH is confirmed by treatment of active targeted nanoparticles for anti–cancer Nano drugs delivery across the blood–brain barrier for human brain cancer treatment, Multiple Sclerosis (MS) and Alzheimer's diseases using chemical modifications of anti–cancer Nano drugs or drug–nanoparticles through Zika Virus (ZIKV) nanocarriers under synchrotron radiation with basic dye and reactive remazol dyes, respectively. There is a reduction in pilling of active targeted nanoparticles for anti–cancer Nano drugs delivery across the blood–brain barrier for human brain cancer treatment, Multiple Sclerosis (MS) and Alzheimer's diseases using chemical modifications of anti–cancer Nano drugs or drug–nanoparticles through Zika Virus (ZIKV) nanocarriers under synchrotron radiation after lipase treatment. It is founded that it may be an economical method of treatment for active targeted nanoparticles for anti–cancer Nano drugs delivery across the blood–brain barrier for human brain cancer treatment, Multiple Sclerosis (MS) and Alzheimer's diseases using chemical modifications of anti–cancer Nano drugs or drug–nanoparticles through Zika Virus (ZIKV) nanocarriers under synchrotron radiation and its blends to improve the comfort properties.

Active targeted nanoparticles for anti–cancer Nano drugs delivery across the blood–brain barrier for human brain cancer treatment, Multiple Sclerosis (MS) and Alzheimer's diseases using chemical modifications of anti–cancer Nano drugs or drug–nanoparticles through Zika Virus (ZIKV) nanocarriers under synchrotron radiation is a novel immunosuppressant for using in auto-immuno diseases and transplantation. This synthetic analogue of myriocin reduces the number of blood lymphocytes by redirecting theme to the lymph node. Active targeted nanoparticles for anti–cancer Nano drugs delivery across the blood–brain barrier for human brain cancer treatment, Multiple Sclerosis (MS) and Alzheimer's diseases using chemical modifications of anti–cancer Nano drugs or drug–nanoparticles through Zika Virus (ZIKV) nanocarriers under synchrotron radiation is the first Sphingosin–1–Phosphate (S1P) receptor modulator. In Multiple Sclerosis (MS) and Alzheimer's diseases, lymphocytes that circulate in the central nervous system (e.g. the brain and spinal cord) attack myelin sheath that surrounds and protect nerve fibers (Axons). Active targeted nanoparticles for anti–cancer Nano drugs delivery across the blood–brain barrier for human brain cancer treatment, Multiple Sclerosis (MS) and Alzheimer's diseases using chemical modifications of anti–cancer Nano drugs or drug–nanoparticles through Zika Virus (ZIKV) nanocarriers under synchrotron radiation inhibits lymphocytes (T, B cells) recirculating. Clinical results after using active targeted nanoparticles for anti–cancer Nano drugs delivery across the blood–brain barrier for human brain cancer treatment, Multiple Sclerosis (MS) and Alzheimer's diseases using chemical modifications of anti–cancer Nano drugs or drug–nanoparticles through Zika Virus (ZIKV) nanocarriers under synchrotron radiation showed that fingolimode reduced the rate of relapses more than 75% and inflammatory diseases activity as measured by Magnetic Resonance Imaging (MRI) up to 85%. In this short communication, derivative of active targeted nanoparticles for anti–cancer Nano drugs delivery across the blood–brain barrier for human brain cancer treatment, Multiple Sclerosis (MS) and Alzheimer's diseases using chemical modifications of anti–cancer Nano drugs or drug–nanoparticles through Zika Virus (ZIKV) nanocarriers under synchrotron radiation such as H–*d*–Pro–FTY720, Boc–*d*– Pro–FTY720, H–*d*–Ala– FTY720, Boc–*d*–Ala–FTY72, for studies further pharmaceutical and neurological effect, were synthesized[43-50].

Over the past decade, there has been an increasing interest in using active targeted nanoparticles for anti–cancer Nano drugs delivery across the blood–brain barrier for human brain cancer treatment, Multiple Sclerosis (MS) and Alzheimer's diseases using chemical modifications of anti–cancer Nano drugs or drug–nanoparticles through Zika Virus (ZIKV) nanocarriers under synchrotron radiation for therapeutic goals in particular cancer therapy. The development of smart targeted nanoparticles (NPs) that can direct anti–cancer Nano drugs at a sustained rate to human cancer stem cells may cause better efficacy and lower toxicity for treating primary and advanced metastatic tumors. Furthermore, over the past decade, a wide variety of antibody–based targeting nanomolecules have been assessed for their potential application in cancer therapy. A novel class of nanomolecules, referred to as nucleic acid ligands (aptamers), has been developed that may rival antibodies in its potential for therapeutic and diagnostic applications. Aptamers are DNA or RNA oligonucleotides or modified DNA or RNA oligonucleotides that fold by intramolecular interaction into unique conformations with ligand–binding characteristics. Alireza Heidari and his co–workers at the BioSpectroscopy Core Research Laboratory at Faculty of Chemistry, California South University (CSU), Irvine, California, USA reported the synthesis and characterization of untrafine particles of some selected anti–cancer Nano drugs by sonochemical method via controlling the synthesized condition, reaction temperature and surfactant concentration were found to be central factor in controlling production morphology and no fundamental bonding change in the anti–cancer nanomolecules after preparation[51-73].

References

1. Heidari, A., Brown, C. Study of Composition and Morphology of Cadmium Oxide (CdO) Nanoparticles for Eliminating Cancer Cells. (2015) Journal of Nanomedicine Research 2(5): 20.
Pubmed | Crossref | Others

2. Heidari, A., Brown, C. Study of Surface Morphological, Phytochemical and Structural Characteristics of Rhodium (III) Oxide (Rh_2O_3) Nanoparticles. (2015) International Journal of Pharmacology, Phytochemistry and Ethnomedicine 1: 15–19.
Pubmed | Crossref | Others

3. Heidari, A. An Experimental Biospectroscopic Study on Seminal Plasma in Determination of Semen Quality for Evaluation of Male Infertility. (2016) Int J Adv Technol 7: e007.
Pubmed | Crossref | Others

4. Heidari, A. Extraction and Preconcentration of N–Tolyl–Sulfonyl–Phosphoramid–Saeure–Dichlorid as an Anti–Cancer Drug from Plants: A Pharmacognosy Study. (2016) J Pharmacogn Nat Prod 2: e103.
Pubmed | Crossref | Others

5. Heidari, A. A Thermodynamic Study on Hydration and Dehydration of DNA and RNA−Amphiphile Complexes. (2016) J Bioeng Biomed Sci S: 006.
Pubmed | Crossref | Others

6. Heidari, A. Computational Studies on Molecular Structures and Carbonyl and Ketene Group's Effects of Singlet and Triplet Energies of Azidoketene O=C=CH–NNN and Isocyanatoketene O=C=CH–N=C=O. (2016) J Appl Computat Math 5: e142.
Pubmed | Crossref | Others

7. Heidari, A. Study of Irradiations to Enhance the Induces the Dissociation of Hydrogen Bonds between Peptide Chains and Transition from Helix Structure to Random Coil Structure Using ATR–FTIR, Raman and ^{1}HNMR Spectroscopies. (2016) J Biomol Res Ther 5: e146.
Pubmed | Crossref | Others

8. Heidari, A. Future Prospects of Point Fluorescence Spectroscopy, Fluorescence Imaging and Fluorescence Endoscopy in Photodynamic Therapy (PDT) for Cancer Cells. (2016) J Bioanal Biomed 8: e135.
Pubmed | Crossref | Others

9. Heidari, A. Bio–Spectroscopic Study of DNA Density and Color Role as Determining Factor for Absorbed. Irradiation in Cancer Cells. (2016) Adv Cancer Prev 1: e102.
Pubmed | Crossref | Others

10. Heidari, A. Manufacturing Process of Solar Cells Using Cadmium Oxide (CdO) and Rhodium (III) Oxide (Rh_2O_3) Nanoparticles. (2016) J Biotechnol Biomater 6: e125.
Pubmed | Crossref | Others

11. Heidari, A. A Novel Experimental and Computational Approach to Photobiosimulation of Telomeric DNA/RNA: A Biospectroscopic and Photobiological Study. (2016) J Res Development 4: 144.
Pubmed | Crossref | Others

12. Heidari, A. Biochemical and Pharmacodynamical Study of Microporous Molecularly Imprinted Polymer Selective for Vancomycin, Teicoplanin, Oritavancin, Telavancin and Dalbavancin Binding. (2016) Biochem Physiol 5: e146.
Pubmed | Crossref | Others

13. Heidari, A. Anti–Cancer Effect of UV Irradiation at Presence of Cadmium Oxide (CdO) Nanoparticles on DNA of Cancer Cells: A Photodynamic Therapy Study. (2016) Arch Cancer Res 4: 1.
Pubmed | Crossref | Others

14. Heidari, A. Biospectroscopic Study on Multi–Component Reactions (MCRs) in Two A–Type and B–Type Conformations of Nucleic Acids to Determine Ligand Binding Modes, Binding Constant and Stability of Nucleic Acids in Cadmium Oxide (CdO) Nanoparticles–Nucleic Acids Complexes as Anti–Cancer Drugs. (2016) Arch Cancer Res 4: 2.
Pubmed | Crossref | Others

15. Heidari, A. "Simulation of Temperature Distribution of DNA/RNA of Human Cancer Cells Using Time–Dependent Bio–Heat Equation and Nd: YAG Lasers". (2016) Arch Cancer Res 4: 2.
Pubmed | Crossref | Others

16. Heidari, A. Quantitative Structure–Activity Relationship (QSAR) Approximation for Cadmium Oxide (CdO) and Rhodium (III) Oxide (Rh_2O_3) Nanoparticles as Anti–Cancer Drugs for the Catalytic Formation of Proviral DNA from Viral RNA Using Multiple Linear and Non–Linear Correlation Approach. (2016) Ann Clin Lab Res 4: 1.
Pubmed | Crossref | Others

17. Heidari A. Biomedical Study of Cancer Cells DNA Therapy Using Laser Irradiations at Presence of Intelligent Nanoparticles. (2016) J Biomedical Sci 5: 2.
Pubmed | Crossref | Others

18. Heidari, A. Measurement the Amount of Vitamin D2 (Ergocalciferol), Vitamin D3 (Cholecalciferol) and Absorbable Calcium (Ca^{2+}), Iron (II) (Fe^{2+}), Magnesium (Mg^{2+}), Phosphate (PO^{4-}) and Zinc (Zn^{2+}) in Apricot Using High–Performance Liquid Chromatography (HPLC) and Spectroscopic Techniques. (2016) J Biom Biostat 7: 292.
Pubmed | Crossref | Others

19. Heidari, A. Spectroscopy and Quantum Mechanics of the Helium Dimer (He^{2+}), Neon Dimer (Ne^{2+}), Argon Dimer (Ar^{2+}), Krypton Dimer (Kr^{2+}), Xenon Dimer (Xe^{2+}), Radon Dimer(Rn^{2+}) and Ununoctium Dimer (Uuo^{2+}) Molecular Cations. (2016) J Chem Sci 7: e112.
Pubmed | Crossref | Others

20. Heidari, A. Human Toxicity Photodynamic Therapy Studies on DNA/RNA Complexes as a Promising New Sensitizer for the Treatment of Malignant Tumors Using Bio–Spectroscopic Techniques. (2016) J Drug Metab Toxicol (2016) 7: e129.
Pubmed | Crossref | Others

21. Heidari, A. Novel and Stable Modifications of Intelligent Cadmium Oxide (CdO) Nanoparticles as Anti–Cancer Drug in Formation of Nucleic Acids Complexes for Human Cancer Cells' Treatment. (2016) Biochem Pharmacol (Los Angel) 5: 207.
Pubmed | Crossref | Others

22. Heidari, A. A Combined Computational and QM/MM Molecular Dynamics Study on Boron Nitride Nanotubes (BNNTs), Amorphous Boron Nitride Nanotubes (a–BNNTs) and Hexagonal Boron Nitride Nanotubes (h–BNNTs) as Hydrogen Storage. (2016) Struct Chem Crystallogr Commun 2: 1.
Pubmed | Crossref | Others

23. Heidari, A. Pharmaceutical and Analytical Chemistry Study of Cadmium Oxide (CdO) Nanoparticles Synthesis Methods and Properties as Anti–Cancer Drug and its Effect on Human Cancer Cells. (2016) Pharm Anal Chem Open Access 2: 113.
Pubmed | Crossref | Others

24. Heidari, A. A Chemotherapeutic and Biospectroscopic Investigation of the Interaction of Double–Standard DNA/RNA–Binding Molecules with Cadmium Oxide (CdO) and Rhodium (III) Oxide (Rh_2O_3) Nanoparticles as Anti–Cancer Drugs for Cancer Cells' Treatment. (2016) Chemo Open Access 5: e129.
Pubmed | Crossref | Others

25. Heidari, A. Pharmacokinetics and Experimental Therapeutic Study of DNA and Other Biomolecules Using Lasers: Advantages and Applications. (2016) J Pharmacokinet Exp Ther 1: e005.
Pubmed | Crossref | Others

26. Heidari, A. Determination of Ratio and Stability Constant of DNA/RNA in Human Cancer Cells and Cadmium Oxide (CdO) Nanoparticles Complexes Using Analytical Electrochemical and Spectroscopic Techniques. (2016) Insights Anal Electrochem 2: 1.
Pubmed | Crossref | Others

27. Heidari, A. Discriminate between Antibacterial and Non–Antibacterial Drugs Artificial Neutral Networks of a Multilayer Perceptron (MLP) Type Using a Set of Topological Descriptors. (2016) J Heavy Met Toxicity Dis. 1: 2.
Pubmed | Crossref | Others

28. Heidari, A. Combined Theoretical and Computational Study of the Belousov–Zhabotinsky Chaotic Reaction and Curtius Rearrangement for Synthesis of Mechlorethamine, Cisplatin, Streptozotocin, Cyclophosphamide, Melphalan, Busulphan and BCNU as Anti–Cancer Drugs. (2016) Insights Med Phys 1: 2.
Pubmed | Crossref | Others
29. Heidari, A. A Translational Biomedical Approach to Structural Arrangement of Amino Acids' Complexes: A Combined Theoretical and Computational Study. (2016) Transl Biomed 7: 2.
Pubmed | Crossref | Others
30. Heidari, A. Ab Initio and Density Functional Theory (DFT) Studies of Dynamic NMR Shielding Tensors and Vibrational Frequencies of DNA/RNA and Cadmium Oxide (CdO) Nanoparticles Complexes in Human Cancer Cells. (2016) J Nanomedine Biotherapeutic Discov 6: e144.
Pubmed | Crossref | Others
31. Heidari, A. Molecular Dynamics and Monte–Carlo Simulations for Replacement Sugars in Insulin Resistance, Obesity, LDL Cholesterol, Triglycerides, Metabolic Syndrome, Type 2 Diabetes and Cardiovascular Disease: A Glycobiological Study. (2016) J Glycobiol 5: e111.
Pubmed | Crossref | Others
32. Heidari, A. Synthesis and Study of 5–(Phenylsulfonyl) Amino.–1,3,4–Thiadiazole–2–Sulfonamide as Potential Anti–Pertussis Drug Using Chromatography and Spectroscopy Techniques. (2016) Transl Med (Sunnyvale) 6: e138.
Pubmed | Crossref | Others
33. Heidari, A. Nitrogen, Oxygen, Phosphorus and Sulphur Heterocyclic Anti–Cancer Nano Drugs Separation in the Supercritical Fluid of Ozone (O3) Using Soave–Redlich–Kwong (SRK) and Pang–Robinson (PR) Equations. (2016) Electronic J Biol 12: 4.
Pubmed | Crossref | Others
34. Heidari, A. An Analytical and Computational Infrared Spectroscopic Review of Vibrational Modes in Nucleic Acids. (2016) Austin J Anal Pharm Chem 3(1): 1058.
Pubmed | Crossref | Others
35. Heidari, A., Brown, C. Phase, Composition and Morphology Study and Analysis of Os–Pd/HfC Nanocomposites. (2016) Nano Res Appl. 2: 1.
Pubmed | Crossref | Others
36. Heidari, A., Brown, C. Vibrational Spectroscopic Study of Intensities and Shifts of Symmetric Vibration Modes of Ozone Diluted by Cumene. (2016) International Journal of Advanced Chemistry 4(1): 5–9.
Pubmed | Crossref | Others
37. Heidari, A. Study of the Role of Anti–Cancer Molecules with Different Sizes for Decreasing Corresponding Bulk Tumor Multiple Organs or Tissues. (2016) Arch Can Res. 4: 2.
Pubmed | Crossref | Others
38. Heidari, A. Genomics and Proteomics Studies of Zolpidem, Necopidem, Alpidem, Saripidem, Miroprofen, Zolimidine, Olprinone and Abafungin as Anti–Tumor, Peptide Antibiotics, Antiviral and Central Nervous System (CNS) Drugs. (2016) J Data Mining Genomics & Proteomics 7: e125.
Pubmed | Crossref | Others
39. Heidari, A. Pharmacogenomics and Pharmacoproteomics Studies of Phosphodiesterase–5 (PDE5) Inhibitors and Paclitaxel Albumin–Stabilized Nanoparticles as Sandwiched Anti–Cancer Nano Drugs between Two DNA/RNA Molecules of Human Cancer Cells. (2016) J Pharmacogenomics Pharmacoproteomics 7: e153.
Pubmed | Crossref | Others
40. Heidari, A. Biotranslational Medical and Biospectroscopic Studies of Cadmium Oxide (CdO) Nanoparticles–DNA/RNA Straight and Cycle Chain Complexes as Potent Anti–Viral, Anti–Tumor and Anti–Microbial Drugs: A Clinical Approach. (2016) Transl Biomed 7: 2.
Pubmed | Crossref | Others
41. Heidari, A. A Comparative Study on Simultaneous Determination and Separation of Adsorbed Cadmium Oxide (CdO) Nanoparticles on DNA/RNA of Human Cancer Cells Using Biospectroscopic Techniques and Dielectrophoresis (DEP) Method. (2016) Arch Can Res. 4: 2.
Pubmed | Crossref | Others
42. Heidari, A. Cheminformatics and System Chemistry of Cisplatin, Carboplatin, Nedaplatin, Oxaliplatin, Heptaplatin and Lobaplatin as Anti–Cancer Nano Drugs: A Combined Computational and Experimental Study. (2016) J Inform Data Min 1: 3.
Pubmed | Crossref | Others
43. Heidari, A. Linear and Non–Linear Quantitative Structure–Anti–Cancer–Activity Relationship (QSACAR) Study of Hydrous Ruthenium (IV) Oxide (RuO2) Nanoparticles as Non–Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Anti–Cancer Nano Drugs. (2016) J Integr Oncol 5: e110.
Pubmed | Crossref | Others
44. Heidari, A. Synthesis, Characterization and Biospectroscopic Studies of Cadmium Oxide (CdO) Nanoparticles–Nucleic Acids Complexes Absence of Soluble Polymer as a Protective Agent Using Nucleic Acids Condensation and Solution Reduction Method. (2016) J Nanosci Curr Res 1: e101.
Pubmed | Crossref | Others
45. Heidari, A. Coplanarity and Collinearity of 4'–Dinonyl–2,2'–Bithiazole in One Domain of Bleomycin and Pingyangmycin to be Responsible for Binding of Cadmium Oxide (CdO) Nanoparticles to DNA/RNA Bidentate Ligands as Anti–Tumor Nano Drug. (2016) Int J Drug Dev & Res 8: 007–008.
Pubmed | Crossref | Others
46. Heidari, A. A Pharmacovigilance Study on Linear and Non–Linear Quantitative Structure (Chromatographic) Retention Relationships (QSRR) Models for the Prediction of Retention Time of Anti–Cancer Nano Drugs under Synchrotron Radiations. (2016) J Pharmacovigil 4: e161.
Pubmed | Crossref | Others
47. Heidari, A. Nanotechnology in Preparation of Semipermeable Polymers. (2016) J Adv Chem Eng 6: 157.
Pubmed | Crossref | Others
48. Heidari, A. A Gastrointestinal Study on Linear and Non–Linear Quantitative Structure (Chromatographic) Retention Relationships (QSRR) Models for Analysis 5–Aminosalicylates Nano Particles as Digestive System Nano Drugs under Synchrotron Radiations. (2016) J Gastrointest Dig Syst 6: e119.
Pubmed | Crossref | Others
49. Heidari, A. DNA/RNA Fragmentation and Cytolysis in Human Cancer Cells Treated with Diphthamide Nano Particles Derivatives. (2016) Biomedical Data Mining 5: e102.
Pubmed | Crossref | Others
50. Heidari, A. A Successful Strategy for the Prediction of Solubility in the Construction of Quantitative Structure–Activity Relationship (QSAR) and Quantitative Structure–Property Relationship (QSPR) under Synchrotron Radiations Using Genetic Function Approximation (GFA) Algorithm. (2016) J Mol Biol Biotechnol 1: 1.
Pubmed | Crossref | Others
51. Heidari, A. Computational Study on Molecular Structures of C20, C60, C240, C540, C960, C2160 and C3840 Fullerene Nano Molecules under Synchrotron Radiations Using Fuzzy Logic. (2016) J Material Sci Eng 5: 282.
Pubmed | Crossref | Others
52. Heidari, A. Graph Theoretical Analysis of Zigzag Polyhexamethylene Biguanide, Polyhexamethylene Adipamide, Polyhexamethylene Biguanide Gauze and Polyhexamethylene Biguanide Hydrochloride (PHMB) Boron Nitride Nanotubes (BNNTs), Amorphous Boron Nitride Nanotubes (a–BNNTs) and Hexagonal Boron Nitride Nanotubes (h–BNNTs). (2016) J Appl Computat Math 5: e143.
Pubmed | Crossref | Others

53. Heidari, A. The Impact of High Resolution Imaging on Diagnosis. (2016) Int J Clin Med Imaging 3: 1000e101.
Pubmed | Crossref | Others
54. Heidari, A. A Comparative Study of Conformational Behavior of Isotretinoin (13–Cis Retinoic Acid) and Tretinoin (All–Trans Retinoic Acid (ATRA)) Nano Particles as Anti–Cancer Nano Drugs under Synchrotron Radiations Using Hartree–Fock (HF) and Density Functional Theory (DFT) Methods. (2016) Insights in Biomed 1: 2.
Pubmed | Crossref | Others
55. Heidari, A. Advances in Logic, Operations and Computational Mathematics. (2016) J Appl Computat Math 5: 5.
Pubmed | Crossref | Others
56. A. Heidari, Mathematical Equations in Predicting Physical Behavior. (2016) J Appl Computat Math 5: 5.
Pubmed | Crossref | Others
57. Heidari, A. Chemotherapy a Last Resort for Cancer Treatment. (2016) Chemo Open Access 5: 4.
Pubmed | Crossref | Others
58. Heidari, A. Separation and Pre–Concentration of Metal Cations–DNA/RNA Chelates Using Molecular Beam Mass Spectrometry with Tunable Vacuum Ultraviolet (VUV) Synchrotron Radiation and Various Analytical Methods. (2016) Mass Spectrom Purif Tech 2: e101.
Pubmed | Crossref | Others
59. Heidari, A. Yoctosecond Quantitative Structure–Activity Relationship (QSAR) and Quantitative Structure–Property Relationship (QSPR) under Synchrotron Radiations Studies for Prediction of Solubility of Anti–Cancer Nano Drugs in Aqueous Solutions Using Genetic Function Approximation (GFA) Algorithm. (2016) Insight Pharm Res. 1: 1.
Pubmed | Crossref | Others
60. Heidari, A. Cancer Risk Prediction and Assessment in Human Cells under Synchrotron Radiations Using Quantitative Structure Activity Relationship (QSAR) and Quantitative Structure Properties Relationship (QSPR) Studies. (2016) Int J Clin Med Imaging 3: 516.
Pubmed | Crossref | Others
61. Heidari, A. A Novel Approach to Biology, Electronic. (2016) J Biol 12: 4.
Pubmed | Crossref | Others
62. Heidari, A. Innovative Biomedical Equipment's for Diagnosis and Treatment. (2016) J Bioengineer & Biomedical Sci 6: 2.
Pubmed | Crossref | Others
63. Heidari, A. Integrating Precision Cancer Medicine into Healthcare, Medicare Reimbursement Changes and the Practice of Oncology. Trends in Oncology Medicine and Practices. (2016) J Oncol Med & Pract 1: 2.
Pubmed | Crossref | Others
64. Heidari, A. Promoting Convergence in Biomedical and Biomaterials Sciences and Silk Proteins for Biomedical and Biomaterials Applications: An Introduction to Materials in Medicine and Bioengineering Perspectives. (2016) J Bioengineer & Biomedical Sci 6: 3.
Pubmed | Crossref | Others
65. Heidari, A. X–Ray Fluorescence and X–Ray Diffraction Analysis on Discrete Element Modeling of Nano Powder Metallurgy Processes in Optimal Container Design. (2017) J Powder Metall Min 6: 1.
Pubmed | Crossref | Others
66. Heidari, A. Biomolecular Spectroscopy and Dynamics of Nano–Sized Molecules and Clusters as Cross–Linking–Induced Anti–Cancer and Immune–Oncology Nano Drugs Delivery in DNA/RNA of Human Cancer Cells' Membranes under Synchrotron Radiations: A Payload–Based Perspective. (2017) Arch Chem Res 1: 2.
Pubmed | Crossref | Others
67. Heidari, A. Deficiencies in Repair of Double–Standard DNA/RNA–Binding Molecules Identified in Many Types of Solid and Liquid Tumors Oncology in Human Body for Advancing Cancer Immunotherapy Using Computer Simulations and Data Analysis. (2017) J Appl Bioinforma Comput Biol 6: 1.
Pubmed | Crossref | Others
68. Heidari, A. Electronic Coupling among the Five Nanomolecules Shuts Down Quantum Tunneling in the Presence and Absence of an Applied Magnetic Field for Indication of the Dimer or other Provide Different Influences on the Magnetic Behavior of Single Molecular Magnets (SMMs) as Qubits for Quantum Computing. (2017) Glob J Res Rev 4: 2.
Pubmed | Crossref | Others
69. Heidari, A. Polymorphism in Nano–Sized Graphene Ligand–Induced Transformation of Au38–xAgx/xCux(SPh–tBu)24 to Au36–xAgx/xCux(SPh–tBu)24 (x = 1–12) Nanomolecules for Synthesis of Au144–xAgx/xCux(SR)60, (SC4)60, (SC6)60, (SC12)60, (PET)60, (p–MBA)60, (F)60, (Cl)60, (Br)60, (I)60, (At)60, (Uus)60 and (SC6H13)60. Nano Clusters as Anti–Cancer Nano Drugs. (2017) J Nanomater Mol Nanotechnol 6: 3.
Pubmed | Crossref | Others
70. Heidari, A. Biomedical Resource Oncology and Data Mining to Enable Resource Discovery in Medical, Medicinal, Clinical, Pharmaceutical, Chemical and Translational Research and Their Applications in Cancer Research. (2017) Int J Biomed Data Min 6: e103.
Pubmed | Crossref | Others
71. Heidari, A. Study of Synthesis, Pharmacokinetics, Pharmacodynamics, Dosing, Stability, Safety and Efficacy of Olympiadane Nanomolecules as Agent for Cancer Enzymotherapy, Immunotherapy, Chemotherapy, Radiotherapy, Hormone Therapy and Targeted Therapy under Synchrotorn Radiation. (2017) J Dev Drugs 6: e154.
Pubmed | Crossref | Others
72. Heidari, A. A Novel Approach to Future Horizon of Top Seven Biomedical Research Topics to Watch in 2017: Alzheimer's, Ebola, Hypersomnia, Human Immunodeficiency Virus (HIV), Tuberculosis (TB), Microbiome/Antibiotic Resistance and Endovascular Stroke. (2017) J Bioengineer & Biomedical Sci 7: e127.
Pubmed | Crossref | Others
73. Heidari, A. Opinion on Computational Fluid Dynamics (CFD) Technique. (2017) Fluid Mech Open Acc 4: 157.
Pubmed | Crossref | Others